FDA Approvals Provide Advances for a Range of Cancer Types
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...
Category: Policy
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to...
Every two minutes, a woman somewhere in the world dies of cervical cancer. That harrowing statistic, shared by Anna R....
In the past year, the number of American teenagers using tobacco products has increased by nearly 40 percent, reversing...
The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the...
During late March and early April, the U.S. Food and Drug Administration (FDA) made several decisions that have increased...
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Like many Americans, Dr. Jill Biden has been personally affected by cancer. Friends, her parents, and her son Beau...